Adjuvant chemotherapy of colon cancer current strategies

European Journal of Cancer, Supplement

Volumn 6, Issue 14, 2008, Pages 60-63

  Barone, Carlo ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Adjuvant chemotherapy; Colon cancer

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; VASCULOTROPIN ANTIBODY;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CLINICAL TRIAL; COLON CANCER; CONTINUOUS INFUSION; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; RISK REDUCTION; THERAPY DELAY; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 55649085956     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcsup.2008.06.024     Document Type: Article

References (28)

1. Wolmark N., et al. Post-operative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01. J Natl Cancer Inst 80 (1998) 30-36
2. Moertel C.G., et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. New Engl J Med 322 (1990) 352-358
3. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT). Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995;345:939-44.
4. O'Connel M.J., et al. Prospectively randomized trial of post-operative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 16 (1998) 295-300
5. Haller D.G., et al. Phase III study of fluorouracil, leucovorin and levamisole in high risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol 23 (2005) 8671-8678
6. Wolmark N., et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin and levamisole in patients with Dukes' B and C carcinoma of the colon; results from the National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 17 (1999) 3553-3559
7. QUASAR Collaborative Group. Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomized trial. Lancet 2000;355:1588-596.
8. André T., et al. For the GERCOR Group, Paris France: Bimnthly regimen of 5-fluorourcail and leucovorin (LV5FU2) as adjuvant therapy in stage II, and III colon cancer: 4-year results of a randomized trial. J Clin Oncol 21 (2003) 2896-2903
9. Poplin E.A., et al. Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer. J Clin Oncol 23 (2005) 1819-1825
10. Twelves C., et al. Capecitabine as adjuvant treatment for stage III colon cancer. New Engl J Med 352 (2005) 2696-2704
11. Lembersky B.C., et al. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol 24 (2006) 2059-2064
12. André T., et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. New Eng J Med 350 (2004) 2343-2351
13. de Gramont A., et al. Oxaliplatin/5FU/LV in adjuvant colon cancer: Updated efficacy results of the MOSAIC trial, including survival with a median follow-up of six years. J Clin Oncol 25 Suppl. 18 (2007) 4007
14. Kuebler J.P., et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 25 (2007) 2198-2204
15. Saltz L.B., et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol 25 (2007) 3456-3461
16. Van Cutsem E., et al. Randomized Phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid (IF) versus 5-FU/FA (F) in stage III colon cancer patients (pts). J Clin Oncol 23 Suppl. 16 (2005) LBA8
17. Sargent D.J., et al. End points for colon cancer adjuvant trials: observations and recommendation based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. J Clin Oncol 25 (2007) 4569-4574
18. Schippinger W., et al. A prospective randomized Phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer. Br J Cancer 97 (2007) 1021-1027
19. QUASAR Collaborative Group. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomized study. Lancet 370 (2007) 2020-2029
20. Figueredo A., et al. Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group. J Clin Oncol 22 (2004) 3395-3407
21. Benson III A.B., et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22 (2004) 3408-3419
22. Hershman D., et al. Timing of adjuvant chemotherapy initiation after surgery for stage III colon cancer. Cancer 107 (2006) 2581-2588
23. Chau I., et al. A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol 16 (2005) 549-557
24. André T., et al. Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1. J Clin Oncol 25 (2007) 3732-3738
25. Lievre A., et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66 (2006) 3992-3995
26. Moroni M., et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 6 (2005) 279-286
27. Hecht JR et al. PACCE: an interim analysis of efficacy and safety from a randomized controlled trial of panitumumab with chemotherapy plus bevacizumab (Bev) for metastatic colorectal cancer (mCRC). In: 9th world congress on gastrointestinal cancer, Barcelona; 2007.
28. Van Cutsem E., et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial. J Clin Oncol 25 (2007) 4000